Researcher
Kim De Keersmaecker
- Disciplines:Cancer biology
Affiliations
- Laboratory for Disease Mechanisms in Cancer (Division)
Responsible
From1 Oct 2016 → Today - Laboratory for Disease Mechanisms in Cancer (Division)
Member
From1 Oct 2014 → Today - Department of Human Genetics (Department)
Member
From1 Oct 2013 → 30 Sep 2014 - Laboratory of Molecular Biology of Leukemia (VIB-KU Leuven) (Division)
Member
From1 Mar 2009 → 30 Sep 2015
Projects
1 - 10 of 42
- Raising the voice of silent mutations in cancerFrom1 Oct 2023 → TodayFunding: BOF - postdoctoral mandates
- Deregulated mRNA transcription and protein translation in the transformation of normal T-cells to malignant cells.From1 Jan 2023 → TodayFunding: BOF - iBOF
- Serine/glycine synthesis addiction in acute lymphoblastic leukemia and resulting therapeutic opportunitiesFrom4 Jul 2021 → TodayFunding: FWO fellowships
- Serine/glycine synthesis addiction in acute lymphoblastic leukemia and resulting therapeutic opportunitiesFrom1 Mar 2021 → TodayFunding: Foundations, funds and other with scientific goal
- VyCAP single cell isolation platform for high-quality single-cell analysisFrom1 Jan 2021 → 31 Dec 2022Funding: BOF - scientific equipment program
- Role of -1 programmed ribosomal frameshifting dysregulation on the JAK2 oncogeneFrom25 Jul 2020 → TodayFunding: FWO fellowships
- Silent mutations in cancerFrom1 May 2020 → TodayFunding: H2020 - Frontier Research (ERC)
- The role of NKX2-1 in T-cell acute lymphoblastic leukemia and NKX2-1 cooperation with the ribosomal RPL10 R98S and NOTCH1 mutations.From1 Jan 2020 → 31 Dec 2023Funding: FWO research project (including WEAVE projects)
- Role of PTEN dysregulation downstream of ribosomal protein RPL5/RPL11 lesions in cancer.From1 Jan 2020 → 31 Dec 2023Funding: FWO research project (including WEAVE projects)
- Fidelity of translation in healthy agingFrom26 Sep 2019 → 26 Sep 2023Funding: BOF - doctoral mandates
Publications
81 - 90 of 90
- Placental Growth Factor: a Novel, Stromal-Derived Target in Human CML(2009)
Authors: Sonja Loges, Thomas Schmidt, Christa Maes, Bart Jonckx, Ria Kleppe, Kim De Keersmaecker, Marc Tjwa, Thomas Schenk, Karolien Beel, Peter Carmeliet, et al.
Pages: 23 - 23 - JAK1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines(2009)
Authors: Michaël Porcu, Jan Cools, Kim De Keersmaecker
Pages: 435 - 437 - Oncogenic Transcriptional Programs Controlled by TLX1/HOX11 and TLX3/HOX11L2 in T-ALL(2009)
Authors: Giusy Della Gatta, Teresa Palomero, Maria Luisa Sulis, Xavier Sole, Wei Keat Lim, Kim De Keersmaecker, Pedro Jose Real Luna, Valeria Tosello, Fotini Gounari, Barbara Kee, et al.
Pages: 282 - 283 - The HOX11/TLX1 Transcription Factor Oncogene Induces Chromosomal Aneuploidy in T-ALL(2009)
Authors: Kim De Keersmaecker, Pedro Jose Real Luna, Giusy Della Gatta, Teresa Palomero, Mireia Castillo, Maria Luisa Sulis, Valeria Tosello, Fotini Gounari, Barbara Kee, Jack Lenz, et al.
Pages: 65 - 66 - Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia(2009)
Authors: Carlos Graux, Annelies Simons, Lucienne Michaux, Peter Vandenberghe, Kim De Keersmaecker, Jan Cools
Pages: 125 - 133 - Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases(2008)
Authors: Kim De Keersmaecker, Jan Cools
Pages: 2208 - 2216 - Evaluation of the Role of PIGF and the Therapeutic Potential of Anti-PIGF in BCR/ABL plus Leukemia(2008)
Authors: Sonja Loges, Thomas Schmidt, Ria Kleppe, Kim De Keersmaecker, Marc Tjwa, Christa Maes, Christiane DeWolf-Peeters, Peter Carmeliet, Jan Cools, Jean-Marie Stassen, et al.
Pages: 399 - 400 - Kinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore(2008)
Authors: Kim De Keersmaecker, Sebastian Munck, Peter Marynen
Pages: 134 - 142 - ABL1 fusions in T cell acute lymphoblastic leukemia(2008)
Authors: Kim De Keersmaecker, Jan Cools
Pages: 245 - 255 - In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia(2008)
Authors: Kim De Keersmaecker, Peter Vandenberghe, Peter Marynen, Jan Cools
Pages: 533 - 542
Patents
1 - 3 of 3